Effects of insulin-like growth factor binding protein 3 on cell growth and tumorigenesis in oral squamous cell carcinoma

por Xu, Hong-Yuan, Zhu, Dong-Wang, Zhong, Lai-Ping, Zhang, Zhi-Yuan, Yang, Cheng-Zhe, Yang, Xiao, Zhang, Peng
Publicado 2019

Mechanism of sensitivity to cisplatin, docetaxel, and 5‐fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpressio...

por Zhao, Tong‐Chao, Zhou, Zhi‐Hang, Ju, Wu‐Tong, Liang, Si‐Yuan, Tang, Xiao, Zhu, Dong‐Wang, Zhang, Zhi‐Yuan, Zhong, Lai‐Ping
Publicado 2021

Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo

por Liang, Si-yuan, Zhao, Tong-chao, Zhou, Zhi-hang, Ju, Wu-tong, Liu, Ying, Tan, Yi-ran, Zhu, Dong-wang, Zhang, Zhi-yuan, Zhong, Lai-ping
Publicado 2021

Stathmin guides personalized therapy in oral squamous cell carcinoma

por Ju, Wu‐tong, Ma, Hai‐long, Zhao, Tong‐Chao, Liang, Si‐yuan, Zhu, Dong‐wang, Wang, Li‐zhen, Li, Jiang, Zhang, Zhi‐yuan, Zhou, Ge, Zhong, Lai‐ping
Publicado 2020

Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade

por Zhu, Dong-wang, Liu, Ying, Yang, Xiao, Yang, Cheng-zhe, Ma, Jie, Yang, Xi, Qiao, Jin-ke, Wang, Li-zhen, Li, Jiang, Zhang, Chen-ping, Zhang, Zhi-yuan, Zhong, Lai-ping
Publicado 2013

Overcoming chemotherapy resistance using pH-sensitive hollow MnO(2) nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma

por Zhou, Zhi-hang, Liang, Si-yuan, Zhao, Tong-chao, Chen, Xu-zhuo, Cao, Xian-kun, Qi, Ming, Huang, Ying-ying, Ju, Wu-tong, Yang, Meng, Zhu, Dong-wang, Pang, Yi-chuan, Zhong, Lai-ping
Publicado 2021

Mutant GDF15 presents a poor prognostic outcome for patients with oral squamous cell carcinoma

por Ma, Jie, Tang, Xiao, Sun, Wen-wen, Liu, Ying, Tan, Yi-ran, Ma, Hai-long, Zhu, Dong-wang, Wang, Min, Wang, Li-zhen, Li, Jiang, Tu, Yao-yao, Zhang, Chen-ping, Zhang, Zhi-yuan, Zhong, Lai-ping
Publicado 2015

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

por Ju, Wu-tong, Xia, Rong-hui, Zhu, Dong-wang, Dou, Sheng-jin, Zhu, Guo-pei, Dong, Min-jun, Wang, Li-zhen, Sun, Qi, Zhao, Tong-chao, Zhou, Zhi-hang, Liang, Si-yuan, Huang, Ying-ying, Tang, Yong, Wu, Si-cheng, Xia, Jing, Chen, Shi-qing, Bai, Yue-zong, Li, Jiang, Zhu, Qi, Zhong, Lai-ping
Publicado 2022